胃癌患者血清CEACAM1水平与临床病理特点的关系及其诊断价值
Article Sidebar
Main Article Content
摘要
目的：研究胃癌患者血清癌胚抗原相关细胞黏附分1（CEACAM1）水平，探讨其与胃癌患者临床病理特点及预后的关系，及其在胃癌诊断中的价值。方法：选择我院2018年1月至2018年12月胃癌患者90例作为胃癌组，选择同期健康体检者90例作为对照组。采用酶联免疫吸附试验（ELISA）法测定血清CEACAM1和CEA水平。结果：胃癌组血清CEACAM1和CEA水平高于对照组（P<0.05）。胃癌患者血清CEACAM1水平与TNM分期、浸润深度、分化程度和淋巴结转移有关（P<0.05），与性别和年龄无关（P>0.05）。血清CEACAM1、CEA及两者联合诊断胃癌的ROC曲线AUC分别为0.716、0.828、0.853。血清CEACAM1水平与胃癌TNM分期、浸润深度、淋巴结转移呈正相关（r=0.703、0.647、0.666，P<0.05），与分化程度呈负相关（r=-0.690，P<0.05）。多因素Logistic回归分析结果显示：TNM分期高、合并淋巴结转移、血清CEA和CEACAM1水平升高是胃癌预后不良的独立危险因素（P<0.05）。结论：胃癌患者血清CEACAM1水平升高，血清CEACAM1水平可反应胃癌的病情严重程度、提高胃癌的诊断效能，为胃癌预后的独立影响因子。
Article Details
本作品采用知识共享署名 4.0 国际许可协议授权。
参考文献
[1]Ajani JA, D'Amico TA, Bentrem DJ, et al. Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology[J]. J Natl Compr Canc Netw, 2022,20(2):167-192.
[2]Kole C, Charalampakis N, Tsakatikas S, et al. Immunotherapy for gastric cancer: a 2021 update[J]. Immunotherapy, 2022, 14(1):41-64.
[3]Hsu CF, Lin MW, Huang CC, et al. Roles and mechanisms of circulating CEACAM1 in the cirrhosis-related intestinal hyperpermeability: in vitro approach[J]. J Chin Med Assoc, 2021, 84(9):851-859.
[4]Kuriri FA, Burchall G, Alanazi F, et al. Mice Lacking PECAM-1 and Ceacam1 Have Enhanced Platelet Secretion and Thrombus Growth: Novel Link with PAR4[J]. Thromb Haemost, 2022, 122(6):961-973.
[5]Igami K, Uchiumi T, Shiota M, et al. Extracellular vesicles expressing CEACAM proteins in the urine of bladder cancer patients[J]. Cancer Sci, 2022, 113(9):3120-3133.
[6]Li GZ, Doherty GM, Wang J. Surgical Management of Gastric Cancer: A Review[J]. JAMA Surg, 2022, 157(5):446-454.
[7]Mabe K, Inoue K, Kamada T, et al. Endoscopic screening for gastric cancer in Japan: Current status and future perspectives[J]. Dig Endosc, 2022, 34(3):412-419.
[8]DeAngelis AM, Malik M, Britten J, et al. Carcinoembryonic antigen-related cell adhesion molecule 1: a key regulatory protein involved in leiomyoma growth[J]. F S Sci, 2021, 2(4):396-406.
[9]Xie Q, Shang TY, Feng S, et al. Hypoxia Inhibits Proliferation of Human Dermal Lymphatic Endothelial Cells via Downregulation of Carcinoembryonic Antigen-related Cell Adhesion Molecule 1 Expression[J]. Curr Med Sci, 2021, 41(6):1192-1197.
[10]Kang ZP, Wang LX, Liu J, et al. Expression of CEACAM1 and CD105 in Renal Cell Carcinoma and Its Correlation with Microvessel Density[J]. Crit Rev Eukaryot Gene Expr, 2021, 31(1):1-9.
[11]Tam K, Schoppy DW, Shin JH, et al. Assessing the Impact of Targeting CEACAM1 in Head and Neck Squamous Cell Carcinoma[J]. Otolaryngol Head Neck Surg, 2018, 159(1):76-84.
[12]Xu J, Liu B, Ma S, et al. Characterizing the Tumor Suppressor Role of CEACAM1 in Multiple Myeloma[J]. Cell Physiol Biochem, 2018, 45(4):1631-1640.
[13]Luebke AM, Ricken W, Kluth M, et al. Loss of the adhesion molecule CEACAM1 is associated with early biochemical recurrence in TMPRSS2:ERG fusion-positive prostate cancers[J]. Int J Cancer, 2020, 147(2):575-583.
[14]Motawi TM, Zakhary NI, Darwish HA, et al. Significance of Some Non-Invasive Biomarkers in the Early Diagnosis and Staging of Egyptian Breast Cancer Patients[J]. Asian Pac J Cancer Prev, 2020, 21(11):3279-3284.
[15]Lucarini G, Zizzi A, Re M, et al. Prognostic implication of CEACAM1 expression in squamous cell carcinoma of the larynx: Pilot study[J]. Head Neck, 2019, 41(6):1615-1621.
[16]Han ZM, Huang HM, Sun YW.Effect of CEACAM-1 knockdown in human colorectal cancer cells[J]. Oncol Lett, 2018, 16(2):1622-1626.
[17]汪功理,黄永年.结肠癌组织中MMP-2、MMP-9、CEACAM-1的表达水平及其临床意义[J].医学临床研究,2022,39(1):101-104.
[18]徐显昌,周宁,陈志刚.甲状腺癌细针穿刺组织中CEACAM1表达量及其与肿瘤恶性程度的相关性[J].分子诊断与治疗杂志,2020,12(11):1544-1547,1551.
[19]Takeuchi A, Yokoyama S, Nakamori M, et al. Loss of CEACAM1 is associated with poor prognosis and peritoneal dissemination of patients with gastric cancer[J]. Sci Rep, 2019,9(1):12702-12710.
[20]朱为民,黄逸姣,潘棋,陈艳,谢楠岚,浦勇.癌胚抗原黏附分子1对胃癌细胞株AGS生物学特性的影响[J].湖南师范大学学报（医学版）,2017,14(5):13-15.
[21]潘棋,陈艳,向培,黄逸姣,谢楠岚,章烨.CEACAM1和CD34蛋白表达与胃癌侵袭转移的关系[J].基础医学与临床,2017,37(5):705-708.
[22]Sripariwuth E, Piwchan S, Pongcharoen S.Serum Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 Level in Patients with Hepatocellular Carcinoma[J]. Asian Pac J Cancer Prev, 2021, 22(11):3521-3524.
[23]张金令,王青青,魏艳蕾,陈秀霞.血清CEACAM-1、CA199、MIC-1联合检测在胰腺癌诊断中的临床价值[J].分子诊断与治疗杂志,2022,14(1):108-111.
[24]李昆,顾建伟,季峰,龚金星,陈焱.乳腺癌患者血清CEACAM1、TM4SF1水平变化及其临床意义[J].山东医药,2022,62(16):14-18.